Chemotherapy is one of the main modalities in the treatment of cancer, but with the cost of unspecific killing of normal cells and considerable systemic toxicity. Encapsulation of the drug(s) in biodegradable nanoparticles (NPs) has the potential to reduce the side effects and simultaneously keep a high dose of the active drug in the tumor by utilizing the enhanced permeation and retention (EPR) effect, and also through active targeting of the NPs. We are collaborating with different partners who produce NPs, and have obtained promising data using poly(alkyl cyanoacrylate) (PACA) nanoparticles (produced by Sintef) in breast cancer PDX models. The project is performed in close collaboration with Prof Kirsten Sandvig, Department of Molecular Cell Biology, Institute for Cancer Research, and in a newly funded project (Cancer Society, 2019-21) we will actively target the PACA particles to the tumor cells.
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
Int J Pharm, 597, 120217 (in press)
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)